Finoriq research workspace
ARDELYX, INC. (ARDX) Institutional Holdings & 13F Ownership
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs. Review ARDX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Company
- ARDELYX, INC. (ARDX)
- Ticker
- ARDX
- Market Cap
- $1.3B
- Latest Price
- $5.14
- Industry
- Biotech & Pharma
ARDELYX, INC. (ARDX) Top Institutional Holders
Top current 13F holders indexed for ARDELYX, INC. (ARDX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Joel GreenblattCIK 0001510387 | $80,595 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.